These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 7751892)

  • 1. Ten-year follow-up study of premenopausal women with metastatic breast cancer: an Eastern Cooperative Oncology Group study.
    Falkson G; Holcroft C; Gelman RS; Tormey DC; Wolter JM; Cummings FJ
    J Clin Oncol; 1995 Jun; 13(6):1453-8. PubMed ID: 7751892
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of metastatic breast cancer in premenopausal women using CAF with or without oophorectomy: an Eastern Cooperative Oncology Group Study.
    Falkson G; Gelman RS; Tormey DC; Falkson CI; Wolter JM; Cummings FJ
    J Clin Oncol; 1987 Jun; 5(6):881-9. PubMed ID: 3585444
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of chemotherapy with chemohormonal therapy as first-line therapy for metastatic, hormone-sensitive breast cancer: An Eastern Cooperative Oncology Group study.
    Sledge GW; Hu P; Falkson G; Tormey D; Abeloff M
    J Clin Oncol; 2000 Jan; 18(2):262-6. PubMed ID: 10637238
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Survival of premenopausal women with metastatic breast cancer. Long-term follow-up of Eastern Cooperative Group and Cancer and Leukemia Group B studies.
    Falkson G; Gelman RS; Leone L; Falkson CI
    Cancer; 1990 Oct; 66(7):1621-9. PubMed ID: 2208013
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Eastern Cooperative Oncology Group experience with cyclophosphamide, adriamycin, and 5-fluorouracil (CAF) in patients with metastatic breast cancer.
    Falkson G; Gelman RS; Tormey DC; Cummings FJ; Carbone PP; Falkson HC
    Cancer; 1985 Jul; 56(2):219-24. PubMed ID: 3839157
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adjuvant CMFVP versus adjuvant CMFVP plus ovariectomy for premenopausal, node-positive, and estrogen receptor-positive breast cancer patients: a Southwest Oncology Group study.
    Rivkin SE; Green S; O'Sullivan J; Cruz AB; Abeloff MD; Jewell WR; Costanzi JJ; Farrar WB; Osborne CK
    J Clin Oncol; 1996 Jan; 14(1):46-51. PubMed ID: 8558219
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A randomized multicenter trial comparing mitoxantrone, cyclophosphamide, and fluorouracil with doxorubicin, cyclophosphamide, and fluorouracil in the therapy of metastatic breast carcinoma.
    Bennett JM; Muss HB; Doroshow JH; Wolff S; Krementz ET; Cartwright K; Dukart G; Reisman A; Schoch I
    J Clin Oncol; 1988 Oct; 6(10):1611-20. PubMed ID: 3049953
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase III study of cyclophosphamide, doxorubicin, and fluorouracil (CAF) plus leucovorin versus CAF for metastatic breast cancer: Cancer and Leukemia Group B 9140.
    Parnes HL; Cirrincione C; Aisner J; Berry DA; Allen SL; Abrams J; Chuang E; Cooper MR; Perry MC; Duggan DB; Szatrowski TP; Henderson IC; Norton L;
    J Clin Oncol; 2003 May; 21(9):1819-24. PubMed ID: 12721259
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chemoendocrine therapy for premenopausal women with axillary lymph node-positive, steroid hormone receptor-positive breast cancer: results from INT 0101 (E5188).
    Davidson NE; O'Neill AM; Vukov AM; Osborne CK; Martino S; White DR; Abeloff MD
    J Clin Oncol; 2005 Sep; 23(25):5973-82. PubMed ID: 16087950
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adjuvant treatment of node-positive breast cancer with cyclophosphamide, doxorubicin, fluorouracil, and vincristine versus cyclophosphamide, methotrexate, and fluorouracil: final report after a 16-year median follow-up duration.
    Misset JL; di Palma M; Delgado M; Plagne R; Chollet P; Fumoleau P; Le Mevel B; Belpomme D; Guerrin J; Fargeot P; Metz R; Ithzaki M; Hill C; Mathé G
    J Clin Oncol; 1996 Apr; 14(4):1136-45. PubMed ID: 8648368
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combination chemotherapy for metastatic or recurrent carcinoma of the breast--a randomized phase III trial comparing CAF versus VATH versus VATH alternating with CMFVP: Cancer and Leukemia Group B Study 8281.
    Aisner J; Cirrincione C; Perloff M; Perry M; Budman D; Abrams J; Panasci L; Muss H; Citron M; Holland J
    J Clin Oncol; 1995 Jun; 13(6):1443-52. PubMed ID: 7751891
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Improved local control and disease-free survival after perioperative chemotherapy for early-stage breast cancer. A European Organization for Research and Treatment of Cancer Breast Cancer Cooperative Group Study.
    Clahsen PC; van de Velde CJ; Julien JP; Floiras JL; Delozier T; Mignolet FY; Sahmoud TM
    J Clin Oncol; 1996 Mar; 14(3):745-53. PubMed ID: 8622020
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sixteen-week multidrug regimen versus cyclophosphamide, doxorubicin, and fluorouracil as adjuvant therapy for node-positive, receptor-negative breast cancer: an Intergroup study.
    Fetting JH; Gray R; Fairclough DL; Smith TJ; Margolin KA; Citron ML; Grove-Conrad M; Cella D; Pandya K; Robert N; Henderson IC; Osborne CK; Abeloff MD
    J Clin Oncol; 1998 Jul; 16(7):2382-91. PubMed ID: 9667255
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cyclophosphamide and fluorouracil combined with mitoxantrone versus doxorubicin for breast cancer: superiority of doxorubicin.
    Stewart DJ; Evans WK; Shepherd FA; Wilson KS; Pritchard KI; Trudeau ME; Wilson JJ; Martz K
    J Clin Oncol; 1997 May; 15(5):1897-905. PubMed ID: 9164200
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cyclophosphamide, doxorubicin and fluorouracil (CAF) plus depo-buserelin in the treatment of premenopausal women with metastatic breast cancer.
    Falkson CI; Falkson HC; Falkson G
    Ann Oncol; 1992 Dec; 3(10):849-53. PubMed ID: 1286048
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Early start of adjuvant chemotherapy may improve treatment outcome for premenopausal breast cancer patients with tumors not expressing estrogen receptors. The International Breast Cancer Study Group.
    Colleoni M; Bonetti M; Coates AS; Castiglione-Gertsch M; Gelber RD; Price K; Rudenstam CM; Lindtner J; Collins J; Thürlimann B; Holmberg S; Veronesi A; Marini G; Goldhirsch A
    J Clin Oncol; 2000 Feb; 18(3):584-90. PubMed ID: 10653873
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Duration and reintroduction of adjuvant chemotherapy for node-positive premenopausal breast cancer patients.
    International Breast Cancer Study Group
    J Clin Oncol; 1996 Jun; 14(6):1885-94. PubMed ID: 8656257
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Postoperative radiotherapy in high-risk premenopausal women with breast cancer who receive adjuvant chemotherapy. Danish Breast Cancer Cooperative Group 82b Trial.
    Overgaard M; Hansen PS; Overgaard J; Rose C; Andersson M; Bach F; Kjaer M; Gadeberg CC; Mouridsen HT; Jensen MB; Zedeler K
    N Engl J Med; 1997 Oct; 337(14):949-55. PubMed ID: 9395428
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chemohormonal therapy in advanced carcinoma of the breast: Cancer and Leukemia Group B protocol 8081.
    Perry MC; Kardinal CG; Korzun AH; Ginsberg SJ; Raich PC; Holland JF; Ellison RR; Kopel S; Schilling A; Aisner J
    J Clin Oncol; 1987 Oct; 5(10):1534-45. PubMed ID: 3655856
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adjuvant CMFVP versus tamoxifen versus concurrent CMFVP and tamoxifen for postmenopausal, node-positive, and estrogen receptor-positive breast cancer patients: a Southwest Oncology Group study.
    Rivkin SE; Green S; Metch B; Cruz AB; Abeloff MD; Jewell WR; Costanzi JJ; Farrar WB; Minton JP; Osborne CK
    J Clin Oncol; 1994 Oct; 12(10):2078-85. PubMed ID: 7931477
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.